Летрозол Зентива

Летрозол Зентива (Letrozole) is an oral aromatase inhibitor used for hormone receptor-positive breast cancer in postmenopausal women. This non-steroidal medication helps reduce estrogen levels to slow tumor growth. Suitable for prescription-based therapy under medical supervision.

Letrozole is primarily used to treat early and advanced hormone receptor-positive breast cancer in postmenopausal women. It may be prescribed after surgery or as a first-line therapy when other treatments are unsuitable. The medication works by lowering estrogen production in the body, which can help prevent cancer recurrence or slow disease progression.

Letrozole is taken orally and may help manage symptoms associated with hormone-sensitive conditions by reducing estrogen levels. Users often report stabilization of breast cancer progression during treatment. Common effects include fatigue, hot flashes, and joint pain, which vary by individual.

This medication should only be used under the guidance of a healthcare professional. Patients should inform their doctor about any existing medical conditions, especially bone disorders or liver problems. Regular monitoring may be required to assess treatment progress and manage potential side effects.

Letrozole may interact with hormonal therapies, CYP inhibitors, or other medications affecting estrogen levels. Alcohol and certain supplements could influence its effects. Patients should disclose all current medications and supplements to their healthcare provider before starting treatment.